Maravai Q1 revenue down 19% to $64.2M; net loss widens to $22.7M; FY guide reaffirmed

MARAVAI LIFESCIENCES HOLDINGS, INC.

2024-Q1 EPS reported -$0.09 revenue$64,179,000

Quarterly revenue $64.2M, down 19% YoY; Nucleic Acid Production fell 25% to $46.0M.
Net loss of $22.7M vs $1.3M loss in Q1 2023; Adjusted EBITDA $7.8M vs $23.8M.
Biologics Safety Testing revenue up 3.4% to $18.2M.
Reaffirmed FY2024 revenue guidance $265M–$285M.
Entered non-exclusive CleanCap license agreement with Lonza for mRNA services.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MARAVAI LIFESCIENCES HOLDINGS, INC. updated its first quarter ended March 31, 2024 guidance (reaffirmed).

Period: first quarter ended March 31, 2024
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On May 8, 2024, Maravai LifeSciences Holdings, Inc. issued a press release announcing its financial results for the first quarter of 2024.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

MARAVAI LIFESCIENCES HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001823239-24-000058

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.